Literature DB >> 29713865

[Getting older with rheumatoid arthritis-is there a burnout of the disease?]

J Bauhammer1, C Fiehn2.   

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease. Synovitis is the main pathology and can lead to a progressive destruction of the joints. It is often said that RA "burns out", implying that the inflammation decreases spontaneously in the long term, mostly severe course of RA and reaches a stage with a stable absence of joint inflammation, even without treatment. To test this concept we analyzed the published evidence. Data of historic long-term inception cohorts of patients who have never been treated with antirheumatic drugs and patients who received conventional disease-modifying antirheumatic drugs (DMARD), show that the disease stays active with sustained radiological progression in the majority of patients. At best, the disease can show a milder course with time or a stage of absence of joint inflammation can be reached if patients responded very well to initial drug treatment. Terminating DMARD treatment in this situation bears the risk of a latent progressive joint destruction, the appearance of extra-articular manifestations and an increase in the cardiovascular risk. Hence there is no evidence for the existence of a "burnt out" RA with stable inactive disease without drug treatment in the long-term course. In a modern treatment strategy of RA following the treat-to-target principle and aiming at remission, the term "burnt out" RA should no longer be used.

Entities:  

Keywords:  Disease activity; Disease-modifying antirheumatic drugs; Long-term course; Progression; Remission

Mesh:

Substances:

Year:  2018        PMID: 29713865     DOI: 10.1007/s00393-018-0465-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  27 in total

1.  In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Authors:  Hamed Rezaei; Saedis Saevarsdottir; Kristina Forslind; Kristina Albertsson; Helena Wallin; Johan Bratt; Sofia Ernestam; Pierre Geborek; Ingemar F Pettersson; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2011-09-19       Impact factor: 19.103

2.  LONG REMISSIONS IN RHEUMATOID ARTHRITIS.

Authors:  C L SHORT
Journal:  Medicine (Baltimore)       Date:  1964-05       Impact factor: 1.889

Review 3.  Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.

Authors:  Aleksander Lenert; Petar Lenert
Journal:  Clin Rheumatol       Date:  2016-11-28       Impact factor: 2.980

4.  Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.

Authors:  Dietmar Krause; Bernadette Gabriel; Gertraud Herborn; Juergen Braun; Rolf Rau
Journal:  Clin Rheumatol       Date:  2016-02-26       Impact factor: 2.980

5.  The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.

Authors:  P M Welsing; A M van Gestel; H L Swinkels; L A Kiemeney; P L van Riel
Journal:  Arthritis Rheum       Date:  2001-09

6.  Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidity.

Authors:  Meliha C Kapetanovic; Elisabet Lindqvist; Jan-Åke Nilsson; Pierre Geborek; Tore Saxne; Kerstin Eberhardt
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-03       Impact factor: 4.794

7.  Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.

Authors:  Jeffrey R Curtis; Kristel Luijtens; Arthur Kavanaugh
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

8.  Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality.

Authors:  Nicola J Minaur; Richard K Jacoby; John A Cosh; Gordon Taylor; Johannes J Rasker
Journal:  J Rheumatol Suppl       Date:  2004-03

9.  Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs.

Authors:  Christoph Fiehn; Elisabeth Belke-Voss; Dietmar Krause; Siegfried Wassenberg; Rolf Rau
Journal:  Clin Rheumatol       Date:  2013-08-08       Impact factor: 2.980

10.  Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account.

Authors:  Dörte Huscher; Claudia Sengler; Erika Gromnica-Ihle; Sascha Bischoff; Thorsten Eidner; Wolfgang Ochs; Jutta Richter; Angela Zink
Journal:  Clin Exp Rheumatol       Date:  2013-01-09       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.